Here are two anonymized case studies that illustrate the potential of combining LDN and peptides
Talk to a real person or sign up for early access to new compounds.
That means the autoimmune process is still underway, and will likely show up as additional autoimmune diagnoses over time
Protein expression screening
338 A-357300, which was subsequently developed, has shown anticancer activity in mouse models of cancer, sarcoma, and nervous system tumors, 339,340 and another candidate, METAPi A-800141, which was selected based on affinity selection based on mass spectrometry, has better selectivity and efficacy than A-357300
Yellow: Theres not much proof it works (at least, yet)